PMID- 37987535
OWN - NLM
STAT- Publisher
LR  - 20231121
IS  - 1365-2826 (Electronic)
IS  - 0953-8194 (Linking)
DP  - 2023 Nov 21
TI  - Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A 
      systematic review.
PG  - e13355
LID - 10.1111/jne.13355 [doi]
AB  - Peptide receptor chemoradionuclide therapy (PRCRT), the addition of 
      radiosensitising chemotherapy to peptide receptor radionuclide therapy (PRRT), 
      has been used in individual centres for neuroendocrine neoplasms (NENs), but 
      there are few data to date regarding its efficacy and safety. We conducted a 
      systematic review to document the efficacy and side effect profile of this 
      combination. We searched for studies including >/=5 patients with advanced NENs who 
      received PRCRT. Major databases were searched and supplemented by handsearching 
      of major conferences from 2019 to 2023. Data extracted included 
      clinicopathological characteristics, trial setting and doses of chemotherapy and 
      PRRT administered. Endpoints included overall survival (OS), progression-free 
      survival (PFS) and adverse events (AEs); summarised qualitatively because of the 
      marked heterogeneity in patient populations, trial designs and treatments 
      administered. Eligible studies (24) included: 14 retrospective studies (643 
      patients) and 10 prospective studies (521 patients). For PRRT, most studies used 
      (177) Lu (n = 21), with combination (177) Lu + (90) Y (n = 2), (111) In (n = 1) 
      and (225) Ac (n = 1). Chemotherapy regimens included capecitabine (n = 8), 
      capecitabine and temozolomide (n = 5), 5-fluorouracil (n = 4) or a mixture of 
      regimens (n = 6). Most studies included Grade 1-2 NENs. In prospective studies, 
      median OS exceeded 2 years in most studies (range not reached by end of 
      follow-up-86 months). In retrospective studies, median OS ranged from 7 months to 
      55 months and was not reached in many studies. PFS data ranged from 31 months-not 
      reached in prospective cohorts and from 4 months-not reached in retrospective 
      cohorts. Grade 3/4 AEs were commonly haematological, with majority being 
      reversible or having no ongoing clinical impact. For advanced NENs, PRCRT 
      treatment has demonstrated promising clinical outcomes and was well tolerated, 
      although identified studies were heterogeneous. Further randomised trial data are 
      required to clarify the place of this combination modality in the NEN treatment 
      paradigm.
CI  - (c) 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons 
      Ltd on behalf of British Society for Neuroendocrinology.
FAU - Chan, Dennis S
AU  - Chan DS
AUID- ORCID: 0000-0003-4518-2912
AD  - Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, 
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Kanagaratnam, Aran L
AU  - Kanagaratnam AL
AD  - Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Pavlakis, Nick
AU  - Pavlakis N
AD  - Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, 
      University of Sydney, Sydney, New South Wales, Australia.
AD  - Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South 
      Wales, Australia.
FAU - Chan, David L
AU  - Chan DL
AD  - Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, 
      University of Sydney, Sydney, New South Wales, Australia.
AD  - Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South 
      Wales, Australia.
LA  - eng
GR  - RACP Arnott Research Entry Scholarship in Cancer Research/
GR  - The Australian Rotary Health/Yaxley Family PhD Scholarship/
PT  - Journal Article
PT  - Review
DEP - 20231121
PL  - United States
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
SB  - IM
OTO - NOTNLM
OT  - neuroendocrine neoplasm
OT  - neuroendocrine tumour
OT  - peptide receptor chemoradionuclide therapy
OT  - peptide receptor radionuclide therapy
OT  - radiosensitising chemotherapy
EDAT- 2023/11/21 12:42
MHDA- 2023/11/21 12:42
CRDT- 2023/11/21 07:24
PHST- 2023/09/29 00:00 [revised]
PHST- 2023/04/21 00:00 [received]
PHST- 2023/10/08 00:00 [accepted]
PHST- 2023/11/21 12:42 [medline]
PHST- 2023/11/21 12:42 [pubmed]
PHST- 2023/11/21 07:24 [entrez]
AID - 10.1111/jne.13355 [doi]
PST - aheadofprint
SO  - J Neuroendocrinol. 2023 Nov 21:e13355. doi: 10.1111/jne.13355.